Over-expression of IκB-kinase-ε (IKKε/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines

Prostate

Volumn 69, Issue 7, 2009, Pages 706-718

  Péant, Benjamin ^a   Diallo, Jean Simon ^a   Dufour, Florent ^a   Le Page, Cécile ^a   Delvoye, Nathalie ^a   Saad, Fred ^a,b,c   Mes Masson, Anne Marie ^a,b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cytokine secretion; IKK IKKi; IL 6; IL 8; Prostate cancer

Indexed keywords

I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 6; INTERLEUKIN 8; I KAPPA B KINASE; PROTEIN SERINE THREONINE KINASE; TBK1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL NUCLEUS TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; BIOSYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; MALE; NEOPLASM; PLASMID; PROSTATE TUMOR; SECRETION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-6; INTERLEUKIN-8; MALE; NEOPLASMS, HORMONE-DEPENDENT; NF-KAPPA B; PLASMIDS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; TRANSFECTION;

EID: 65449163494     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20912     Document Type: Article

References (75)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49(1):8-31, 31.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860- 867. (Pubitemid 36019639)
3. Mantovani A. Cancer: Inflammation by remote control. Nature 2005;435(7043):752-753. (Pubitemid 40839716)
4. Liu RS, Ta D, Payne J, Coccia M, Kuus-Reichel K. Generation of murine monoclonal antibodies in serum-free medium. Hybridoma 1998;17(1):69-72. (Pubitemid 28120021)
5. Schindler C, Strehlow I. Cytokines and STAT signaling. Adv Pharmacol 2000;47:113-174.
6. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: How hot is the link? Biochem Pharmacol 2006;72(11):1605-1621.
7. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, Lindquist R, Barrows G, Kreutzer DL. Interleukin-1 family expression inhumanbreast cancer: Interleukin-1 receptor antagonist. Cancer Invest 2000;18(4):293-302.
8. Singer CF, Kronsteiner N, Hudelist G, Marton E, Walter I, Kubista M, Czerwenka K, Schreiber M, Seifert M, Kubista E. Interleukin 1 system and sex steroid receptor expression in human breast cancer: Interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res 2003;9(13):4877-4883.
9. Kurebayashi J. Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications. Breast Cancer 2000;7(2):124-129.
10. Knupfer H, Schmidt R, Stanitz D, Brauckhoff M, Schonfelder M, Preiss R. CYP2C and IL-6 expression in breast cancer. Breast 2004;13(1):28-34. (Pubitemid 38228585)
11. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7(2):285-289. (Pubitemid 32183031)
12. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 2003;48:82-84.
13. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY. Increased serum interleukin- 8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004;10(21):7157-7162. (Pubitemid 39487700)
14. Mettler L, Salmassi A, Heyer M, Schmutzier A, Schollmeyer T, Jonat W. Perioperative levels of interleukin-1 beta and interleukin- 6 in women with breast cancer. Clin Exp Obstet Gynecol 2004;31(1):20-22. (Pubitemid 38200408)
15. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G, Culig Z. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000;191(3):239-244. (Pubitemid 30441246)
16. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 2001;7(9):2941-2948. (Pubitemid 32911405)
17. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38(3):199-207. (Pubitemid 29054936)
18. Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 2000;42(1):1-7. (Pubitemid 30004869)
19. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 2005;64(1):40-49. (Pubitemid 40734737)
20. Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, Montironi R, Waugh DJ. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 2005;11(11):4117-4127. (Pubitemid 40791576)
21. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001;58(6):1008-1015. (Pubitemid 34017290)
22. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001;12(1):33-40. (Pubitemid 32294585)
23. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL- 6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004;91(6):1227. (Pubitemid 38961893)
24. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2000;60(8):2132-2135. (Pubitemid 30225173)
25. Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through upregulation of androgen receptor expression. Clin Cancer Res 2001;7(6):1773-1781. (Pubitemid 32708648)
26. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002;277(9):7076-7085.
27. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin- 6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002;277(41):38087-38094. (Pubitemid 35157768)
28. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005;95(3):497-505. (Pubitemid 41420180)
29. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41(2):127-133. (Pubitemid 29446967)
30. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001;159(6):2159-2165. (Pubitemid 33104270)
31. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J Urol 2000;164(3 Pt 1):722-725. (Pubitemid 30637610)
32. Barnes PJ, Karin M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336(15):1066-1071.
33. Le Page C, Koumakpayi IH, Lessard L, Mes-Masson AM, Saad F. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 2005;65(2):130-140. (Pubitemid 41362280)
34. Chen CD, Sawyers CL. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002;22(8):2862-2870. (Pubitemid 34263006)
35. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: Important mediator or epiphenomenon? J Cell Biochem 2004;91(1):100-117.
36. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002;115(Pt 1):141-151. (Pubitemid 34105537)
37. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC, Rowley D. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 2004;64(17):6082-6090. (Pubitemid 39129408)
38. Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Stringer B. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: Correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 2004;10(7):2466-2472.
39. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004;10(16):5501-5507. (Pubitemid 39100488)
40. Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI, Gupta S. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004;6(4):390-400. (Pubitemid 38924854)
41. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 2003;91(4):417-420. (Pubitemid 36359653)
42. Lessard L, Karakiewicz PI, Bellon-Gagnon P, Alam-Fahmy M, Ismail HA, Mes-Masson AM, Saad F. Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res 2006;12(19):5741-5745. (Pubitemid 44629604)
43. Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM, Saad F. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 2004;10(24):8460-8464. (Pubitemid 40053410)
44. Peant B, Diallo JS, Lessard L, Delvoye N, Le Page C, Saad F, Mes- Masson AM. Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer. Mol Cancer Res 2007;5(1):87-94. (Pubitemid 46246769)
45. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003;300(5622):1148-1151.
46. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003;4(5):491-496. (Pubitemid 36592443)
47. McWhirter SM, Fitzgerald KA, Rosains J, Rowe DC, Golenbock DT, Maniatis T. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc Natl Acad Sci USA 2004;101(1):233-238. (Pubitemid 38084233)
48. Hiscott J, Grandvaux N, Sharma S, Tenoever BR, Servant MJ, Lin R. Convergence of the NF-kappaB and interferon signaling pathways in the regulation of antiviral defense and apoptosis. Ann NY Acad Sci 2003;1010:237-248. (Pubitemid 38264983)
49. Aupperle KR, Yamanishi Y, Bennett BL, Mercurio F, Boyle DL, Firestein GS. Expression and regulation of inducible IkappaB kinase (IKK-i) in human fibroblast-like synoviocytes. Cell Immunol 2001;214(1):54-59. (Pubitemid 34280756)
50. Kravchenko VV, Mathison JC, Schwamborn K, Mercurio F, Ulevitch RJ. IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli. J Biol Chem 2003;278(29):26612-26619. (Pubitemid 36876806)
51. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 2000;42(3):239-242. (Pubitemid 30080423)
52. Konig JE, Senge T, Allhoff EP, Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004;58(2):121-129. (Pubitemid 38160899)
53. Ear T, Cloutier A, McDonald PP. Constitutive nuclear expression of the I kappa B kinase complex and its activation in human neutrophils. J Immunol 2005;175(3):1834-1842. (Pubitemid 41023089)
54. Nagpal ML, Davis J, Lin T. Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. Biochim Biophys Acta 2006;1762(9):811-818. (Pubitemid 44403048)
55. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7(6):429-442. (Pubitemid 46834849)
56. Mesters RM, Florke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996;75(6):902-907. (Pubitemid 26355345)
57. Menges T, Hermans PW, Little SG, Langefeld T, Boning O, Engel J, Sluijter M, de Groot R, Hempelmann G. Plasminogen-activator- inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001;357(9262):1096-1097. (Pubitemid 32322544)
58. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007;97(5):714-721. (Pubitemid 46804314)
59. Kooijman R, Himpe E, Potikanond S, Coppens A. Regulation of interleukin-8 expression in human prostate cancer cells by insulin-like growth factor-I and inflammatory cytokines. Growth Horm IGF Res 2007;17(5):383-391. (Pubitemid 47324303)
60. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998;51(1):161-167.
61. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastases in androgen- independent prostate cancer. Clin Cancer Res 2000;6(5):2104-2119. (Pubitemid 30305111)
62. Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, Sanjo H, Kawai T, Hoshino K, Takeda K, Akira S. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 2004;199(12):1641-1650. (Pubitemid 38821997)
63. Sato M, Tanaka N, Hata N, Oda E, Taniguchi T. Involvement of the IRF family transcription factor IRF-3 in virus-induced activation of the IFN-beta gene. FEBS Lett 1998;425(1):112-116. (Pubitemid 28149751)
64. Lin R, Heylbroeck C, Genin P, Pitha PM, Hiscott J. Essential role of interferon regulatory factor 3 in direct activation of RANTES chemokine transcription. Mol Cell Biol 1999;19(2):959-966. (Pubitemid 29046840)
65. Krasowska-Zoladek A, Banaszewska M, Kraszpulski M, Konat GW. Kinetics of inflammatory response of astrocytes induced by TLR 3 and TLR4 ligation. J Neurosci Res 2007;85(1):205-212. (Pubitemid 46079810)
66. Sanceau J, Kaisho T, Hirano T, Wietzerbin J. Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors. J Biol Chem 1995;270(46):27920-27931.
67. Wang W, Ye L, Li B, Gao B, Zeng Y, Kong L, Fang X, Zheng H, Wu Z, She Y. Up-regulation of IL-6 and TNF-alpha induced by SARS coronavirus spike protein in murine macrophages via NF-kappaB pathway. Virus Res 2007;128(1-2):1-8. (Pubitemid 47242878)
68. Adli M, Baldwin AS. IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser- 536 p65/RelA phosphorylation. J Biol Chem 2006;281(37):26976-26984. (Pubitemid 44401726)
69. Harris J, Oliere S, Sharma S, Sun Q, Lin R, Hiscott J, Grandvaux N. Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKK epsilon. J Immunol 2006;177(4):2527-2535. (Pubitemid 44202170)
70. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane- Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007;129(6):1065-1079. (Pubitemid 46891036)
71. Xiao W, Hodge DR, Wang L, Yang X, Zhang X, Farrar WL. Cooperative functions between nuclear factors NFkappaB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 2004;61(4):354-370. (Pubitemid 39564278)
72. Asschert JG, De Vries EG, De Jong S, Withoff S, Vellenga E. Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: Involvement of AP-1. Int J Cancer 1999;81(2):236-242.
73. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003;56(3):171-182. (Pubitemid 36918167)
74. Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C, Vignon F, Lazennec G. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 2004;23(36):6105-6114. (Pubitemid 39178863)
75. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117(5):1175-1183. (Pubitemid 46718402)